Cargando…

Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model

AIMS: Azithromycin is widely used broad spectrum antibiotic recently used in treatment protocol of COVID-19 for its antiviral and immunomodulatory effects combined with Hydroxychloroquine or alone. Rat models showed that Azithromycin produces oxidative stress, inflammation, and apoptosis of myocardi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansour, Basma S., Salem, Noha A., Kader, Ghada Abdel, Abdel-Alrahman, Gamal, Mahmoud, Omayma M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816566/
https://www.ncbi.nlm.nih.gov/pubmed/33476632
http://dx.doi.org/10.1016/j.lfs.2021.119099
_version_ 1783638468817059840
author Mansour, Basma S.
Salem, Noha A.
Kader, Ghada Abdel
Abdel-Alrahman, Gamal
Mahmoud, Omayma M.
author_facet Mansour, Basma S.
Salem, Noha A.
Kader, Ghada Abdel
Abdel-Alrahman, Gamal
Mahmoud, Omayma M.
author_sort Mansour, Basma S.
collection PubMed
description AIMS: Azithromycin is widely used broad spectrum antibiotic recently used in treatment protocol of COVID-19 for its antiviral and immunomodulatory effects combined with Hydroxychloroquine or alone. Rat models showed that Azithromycin produces oxidative stress, inflammation, and apoptosis of myocardial tissue. Rosuvastatin, a synthetic statin, can attenuate myocardial ischemia with antioxidant and antiapoptotic effects. This study aims to evaluate the probable protective effect of Rosuvastatin against Azithromycin induced cardiotoxicity. MAIN METHOD: Twenty adult male albino rats were divided randomly into four groups, five rats each control, Azithromycin, Rosuvastatin, and Azithromycin +Rosuvastatin groups. Azithromycin 30 mg/kg/day and Rosuvastatin 2 mg/kg/day were administrated for two weeks by an intragastric tube. Twenty-four hours after the last dose, rats were anesthetized and the following measures were carried out; Electrocardiogram, Blood samples for Biochemical analysis of lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). The animals sacrificed, hearts excised, apical part processed for H&E, immunohistochemical staining, and examined by light microscope. The remaining parts of the heart were collected for assessment of Malondialdehyde (MDA) and Reduced Glutathione (GSH). KEY FINDINGS: The results revealed that Rosuvastatin significantly ameliorates ECG changes, biochemical, and Oxidative stress markers alterations of Azithromycin. Histological evaluation from Azithromycin group showed marked areas of degeneration, myofibers disorganization, inflammatory infiltrate, and hemorrhage. Immunohistochemical evaluation showed significant increase in both Caspase 3 and Tumor necrosis factor (TNF) immune stain. Rosuvastatin treated group showed restoration of the cardiac muscle fibers in H&E and Immunohistochemical results. SIGNIFICANCE: We concluded that Rosuvastatin significantly ameliorates the toxic changes of Azithromycin on the heart.
format Online
Article
Text
id pubmed-7816566
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-78165662021-01-21 Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model Mansour, Basma S. Salem, Noha A. Kader, Ghada Abdel Abdel-Alrahman, Gamal Mahmoud, Omayma M. Life Sci Article AIMS: Azithromycin is widely used broad spectrum antibiotic recently used in treatment protocol of COVID-19 for its antiviral and immunomodulatory effects combined with Hydroxychloroquine or alone. Rat models showed that Azithromycin produces oxidative stress, inflammation, and apoptosis of myocardial tissue. Rosuvastatin, a synthetic statin, can attenuate myocardial ischemia with antioxidant and antiapoptotic effects. This study aims to evaluate the probable protective effect of Rosuvastatin against Azithromycin induced cardiotoxicity. MAIN METHOD: Twenty adult male albino rats were divided randomly into four groups, five rats each control, Azithromycin, Rosuvastatin, and Azithromycin +Rosuvastatin groups. Azithromycin 30 mg/kg/day and Rosuvastatin 2 mg/kg/day were administrated for two weeks by an intragastric tube. Twenty-four hours after the last dose, rats were anesthetized and the following measures were carried out; Electrocardiogram, Blood samples for Biochemical analysis of lactate dehydrogenase (LDH), and creatine phosphokinase (CPK). The animals sacrificed, hearts excised, apical part processed for H&E, immunohistochemical staining, and examined by light microscope. The remaining parts of the heart were collected for assessment of Malondialdehyde (MDA) and Reduced Glutathione (GSH). KEY FINDINGS: The results revealed that Rosuvastatin significantly ameliorates ECG changes, biochemical, and Oxidative stress markers alterations of Azithromycin. Histological evaluation from Azithromycin group showed marked areas of degeneration, myofibers disorganization, inflammatory infiltrate, and hemorrhage. Immunohistochemical evaluation showed significant increase in both Caspase 3 and Tumor necrosis factor (TNF) immune stain. Rosuvastatin treated group showed restoration of the cardiac muscle fibers in H&E and Immunohistochemical results. SIGNIFICANCE: We concluded that Rosuvastatin significantly ameliorates the toxic changes of Azithromycin on the heart. Elsevier Inc. 2021-03-15 2021-01-19 /pmc/articles/PMC7816566/ /pubmed/33476632 http://dx.doi.org/10.1016/j.lfs.2021.119099 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Mansour, Basma S.
Salem, Noha A.
Kader, Ghada Abdel
Abdel-Alrahman, Gamal
Mahmoud, Omayma M.
Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model
title Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model
title_full Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model
title_fullStr Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model
title_full_unstemmed Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model
title_short Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model
title_sort protective effect of rosuvastatin on azithromycin induced cardiotoxicity in a rat model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816566/
https://www.ncbi.nlm.nih.gov/pubmed/33476632
http://dx.doi.org/10.1016/j.lfs.2021.119099
work_keys_str_mv AT mansourbasmas protectiveeffectofrosuvastatinonazithromycininducedcardiotoxicityinaratmodel
AT salemnohaa protectiveeffectofrosuvastatinonazithromycininducedcardiotoxicityinaratmodel
AT kaderghadaabdel protectiveeffectofrosuvastatinonazithromycininducedcardiotoxicityinaratmodel
AT abdelalrahmangamal protectiveeffectofrosuvastatinonazithromycininducedcardiotoxicityinaratmodel
AT mahmoudomaymam protectiveeffectofrosuvastatinonazithromycininducedcardiotoxicityinaratmodel